These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27260871)

  • 21. Germline BAP1 mutations predispose to malignant mesothelioma.
    Testa JR; Cheung M; Pei J; Below JE; Tan Y; Sementino E; Cox NJ; Dogan AU; Pass HI; Trusa S; Hesdorffer M; Nasu M; Powers A; Rivera Z; Comertpay S; Tanji M; Gaudino G; Yang H; Carbone M
    Nat Genet; 2011 Aug; 43(10):1022-5. PubMed ID: 21874000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
    Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
    BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
    Hassan R; Morrow B; Thomas A; Walsh T; Lee MK; Gulsuner S; Gadiraju M; Panou V; Gao S; Mian I; Khan J; Raffeld M; Patel S; Xi L; Wei JS; Hesdorffer M; Zhang J; Calzone K; Desai A; Padiernos E; Alewine C; Schrump DS; Steinberg SM; Kindler HL; King MC; Churpek JE
    Proc Natl Acad Sci U S A; 2019 Apr; 116(18):9008-9013. PubMed ID: 30975761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
    Dragon J; Thompson J; MacPherson M; Shukla A
    J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
    Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR
    Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
    Ribeiro C; Campelos S; Moura CS; Machado JC; Justino A; Parente B
    Ann Oncol; 2013 Aug; 24(8):2147-50. PubMed ID: 23585512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
    Travis LB; Fosså SD; Schonfeld SJ; McMaster ML; Lynch CF; Storm H; Hall P; Holowaty E; Andersen A; Pukkala E; Andersson M; Kaijser M; Gospodarowicz M; Joensuu T; Cohen RJ; Boice JD; Dores GM; Gilbert ES
    J Natl Cancer Inst; 2005 Sep; 97(18):1354-65. PubMed ID: 16174857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
    Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
    Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
    Glass C; Sholl LM; Landgraf JR; Chirieac L; Roggli VL
    Am J Surg Pathol; 2020 Feb; 44(2):288-292. PubMed ID: 31567203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic landscape of pleural and peritoneal mesothelioma tumours.
    Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A
    Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant mesothelioma in situ: morphologic features and clinical outcome.
    Churg A; Galateau-Salle F; Roden AC; Attanoos R; von der Thusen JH; Tsao MS; Chang N; De Perrot M; Dacic S
    Mod Pathol; 2020 Feb; 33(2):297-302. PubMed ID: 31375770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
    Ugurluer G; Chang K; Gamez ME; Arnett AL; Jayakrishnan R; Miller RC; Sio TT
    Anticancer Res; 2016 May; 36(5):2331-8. PubMed ID: 27127140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
    Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
    Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.
    Cheung M; Talarchek J; Schindeler K; Saraiva E; Penney LS; Ludman M; Testa JR
    Cancer Genet; 2013 May; 206(5):206-10. PubMed ID: 23849051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.
    Sneddon S; Leon JS; Dick IM; Cadby G; Olsen N; Brims F; Allcock RJ; Moses EK; Melton PE; de Klerk N; Musk AW; Robinson BW; Creaney J
    Gene; 2015 May; 563(1):103-5. PubMed ID: 25796603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated Histogenetic Analysis Reveals
    Bochtler T; Endris V; Reiling A; Leichsenring J; Schweiger MR; Klein S; Stögbauer F; Goeppert B; Schirmacher P; Krämer A; Stenzinger A
    J Natl Compr Canc Netw; 2018 Jun; 16(6):677-682. PubMed ID: 29891518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
    Soeberg MJ; Leigh J; Driscoll T; Armstrong B; Young JM; van Zandwijk N
    Occup Environ Med; 2016 Mar; 73(3):187-94. PubMed ID: 26800709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
    Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
    Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature.
    Del Gobbo A; Fiori S; Gaudioso G; Bonaparte E; Tabano S; Palleschi A; Bosari S; Ferrero S
    Int J Clin Exp Pathol; 2014; 7(5):2484-9. PubMed ID: 24966960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.